期刊文献+

黄豆苷元干预老年冠心病患者血清炎性因子的临床观察 被引量:12

Clinical Observation of Daidzein Intervention on Serum Inflammatory Factors in Senile Patients with Coronary Heart Disease
下载PDF
导出
摘要 目的观察黄豆苷元(Daidzein,DZ)对冠心病患者血清炎性因子的影响。方法40例老年冠心病患者随机分为对照组和用药组各20例。对照组给予常规用药治疗,用药组在常规治疗的基础上加用黄豆苷元片治疗6周,分别在治疗前后测量基础心率(RHR)、血压(BP)、空腹静脉血糖(FPG)、血脂以及炎性因子(hsCRP、IL-6和TNF-α)。结果对照组患者治疗后,除了RHR、BP和hsCRP较治疗前有改变外(P<0·05或P<0·01),其余指标没有变化(P>0·05)。用药组治疗后,RHR、BP、FPG、血脂和各项炎性因子较治疗前和对照组治疗后均有不同程度的下降(P<0·05或P<0·01)。结论黄豆苷元能够有效地抑制老年冠心病患者血清炎性因子的水平,异黄酮类药物对冠状动脉粥样硬化具有抗炎作用。 Objective To observe the effect of daidzein on serum inflammatory factors of senile patients with coronary heart disease (CHD). Methods Forty senile patients with CHD were randomly assigned into the control group and the daidzein group, 20 in each group. Patients in both groups were treated with conventional medicine, while those in the daidzein group were given daidzein Tablets additionally for 6 weeks. The levels of resting heart rate (RHR), blood pressure (BP), fasting plasma glucose (FPG), blood lipids and inflammatory factors, including hsCRP, IL-6 and TNF-α, were measured before and after treatment. Results In the control group, the levels of RHR, BP and hsCRP changed after conventional medicinal treatment (P 〈 0.05 or P 〈 0.01) but other parameters unchanged (P 〉 0.05). While in the daidzein group, all the parameters measured were decreased in different degrees after 6 weeks treatment ( P 〈 0.05 or P 〈 0.01 ), and also showed significant difference as compared with those in the control group respectively (P 〈 0.05 or P 〈 0.01 ). Conclusion Daidzein can effectively decrease the levels serum inflammatory factors in senile patients with CHD, the fact proved that isoflavone has anti-inflammatory effect in patients with coronary atherosclerosis.
出处 《中国中西医结合杂志》 CAS CSCD 北大核心 2006年第1期42-45,共4页 Chinese Journal of Integrated Traditional and Western Medicine
关键词 黄豆苷元 动脉粥样硬化 冠心病 炎性因子 老年人 daidzein atherosclerosis coronary heart disease inflammatory factor senile
  • 引文网络
  • 相关文献

参考文献10

  • 1Ursella S,Mazzone M,Portale G,et al.How to use the C-reac tive protein in cardiac disease? Minerva Cardioangiol 2005;53(1):59-68.
  • 2叶任高 主编.内科学:第5版[M].北京:人民卫生出版社,2000.532-541.
  • 3Mullenix PS,Andersen CA,Starnes BW.Atherosclerosis as inflammation.Ann Vasc Surg 2005; 19 (1):130-138.
  • 4Dijsselbloem N,Vanden Berghe W,De Naeyer A,et al.Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections.Multi-purpose nutraceuticals at the crossroad of hormone replacement,anti-cancer and anti-inflammatory therapy.Biochem Pharmacol 2004; 68 (6):1171-1185.
  • 5Chacko BK,Chandler RT,Mundhekar A,et al.Revealing anti-inflammatory mechanisms of soyisoflavones by flow:modulation of leukocyte-endothelial cell interactions.Am J Physiol Heart Circ Physiol 2005;289(2):H908-915.
  • 6Gottstein N,Ewins BA,Eccleston C,et al.Effect of genistein and daidzein on platelet aggregation and monocyte and endothelial function.Br J Nutr 2003;89(5):607-616.
  • 7Davis JN,Kucuk O,Djuric Z,et al.Soy isoflavone supple mentation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes.Free Radic Biol Med 2001 ;30(11):1293-1302.
  • 8Mezei O,Banz W J,Steger RW,et al.Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells.J Nu tr 2003;133(5):1238-1243.
  • 9Sajadieh A,Nielsen OW,Rasmussen V,et al.Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease.Eur Heart J 2004; 25 (5):363-370.
  • 10Kawakami Y,Tsurugasaki W,Yoshida Y,et al.Regulative actions of dietary soy isoflavone on biological antioxidative system and lipid metabolism in rats.J Agric Food Chem 2004; 52(6):1764-1768.

共引文献145

同被引文献126

引证文献12

二级引证文献66

;
使用帮助 返回顶部